Payment overview · 2025
General Payments
$4,076.87
184 reported records · 28 companies
Healthcare provider profile · identity verified
Eric Justin Brahin, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SAN ANTONIO, TX · NPI 1710201264
Verified facts
What the public records show
CMS Open Payments records show Eric Justin Brahin, MD received $4,076.87 in general payments during 2025 across 184 reported records.
PFIZER INC. accounted for 10.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Fycompa, Nuplazid, Nurtec Odt, Qulipta, Ubrelvy, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vumerity by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Fycompa by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Nurtec Odt by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $435.34 | 10.7% | 20 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $378.05 | 9.3% | 18 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $318.54 | 7.8% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $306.64 | 7.5% | 16 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $281.82 | 6.9% | 13 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $249.75 | 6.1% | 11 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $221.96 | 5.4% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $217.70 | 5.3% | 9 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $202.47 | 5.0% | 9 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $194.01 | 4.8% | 10 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $165.26 | 4.0% | 6 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $138.59 | 3.4% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $124.79 | 3.1% | 6 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $118.84 | 2.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $118.23 | 2.9% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $97.60 | 2.4% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $94.15 | 2.3% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $86.29 | 2.1% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.21 | 1.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.30 | 1.3% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $51.22 | 1.3% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$30.31 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.28 | 0.6% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $25.67 | 0.6% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $22.80 | 0.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.59 | 0.5% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.97 | 0.4% | 1 | 2025 |
| Metacel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.49 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,076.87 | 184 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $391.61 | 18 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $378.05 | 18 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $318.54 | 17 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $281.82 | 13 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $226.97 | 10 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $221.96 | 8 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $217.70 | 9 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $178.56 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $174.41 | 9 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $171.48 | 9 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $165.26 | 6 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $148.70 | 7 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $118.84 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $118.23 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $114.92 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $103.89 | 7 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $103.48 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $94.15 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $86.29 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $79.20 | 3 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $66.21 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $52.04 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $51.30 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $51.30 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $51.22 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $26.28 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $25.67 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| Enspryng Normalized: enspryng |
Biological | Genentech USA, Inc. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| OZOBAX Normalized: ozobax |
Drug | Metacel Pharmaceuticals LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 27 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 66 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 129 | exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
129 | 33 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 826 | 168 |
| Topiramate | Topiramate | 468 | 92 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 396 | 86 |
| Gabapentin | Gabapentin | 378 | 90 |
| Donepezil Hcl | Donepezil Hcl | 321 | 91 |
| Divalproex Sodium | Divalproex Sodium | 315 | 75 |
| Lacosamide | Lacosamide | 240 | 33 |
| Memantine Hcl | Memantine Hcl | 182 | 46 |
| Zonisamide | Zonisamide | 161 | 28 |
| Carbamazepine | Carbamazepine | 142 | 26 |
| Lamotrigine | Lamotrigine | 132 | 24 |
| Ubrelvy | Ubrogepant | 129 | 33 |
| Primidone | Primidone | 123 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 108 | 36 |
| Pregabalin | Pregabalin | 102 | 26 |
| Memantine Hcl Er | Memantine Hcl | 97 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 87 | 26 |
| Aimovig Autoinjector | Erenumab-Aooe | 80 | 11 |
| Oxcarbazepine | Oxcarbazepine | 75 | 18 |
| Phenobarbital | Phenobarbital | 74 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 71 | 14 |
| Propranolol Hcl | Propranolol Hcl | 67 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 66 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 66 | 16 |
| Emgality Pen | Galcanezumab-Gnlm | 65 | suppressed |
| Carbamazepine Er | Carbamazepine | 61 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 60 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 51 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Fycompa | Perampanel | 40 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 39 | 14 |
| Baclofen | Baclofen | 34 | suppressed |
| Briviact | Brivaracetam | 33 | suppressed |
| Vimpat | Lacosamide | 29 | suppressed |
| Botox | Onabotulinumtoxina | 27 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Vumerity | Diroximel Fumarate | 22 | suppressed |
| Qulipta | Atogepant | 20 | suppressed |
| Keppra | Levetiracetam | 19 | suppressed |
| Onfi | Clobazam | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Levetiracetam Er | Levetiracetam | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Kesimpta Pen | Ofatumumab | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Rytary | Carbidopa/Levodopa | 14 | suppressed |
| Dalfampridine Er | Dalfampridine | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Glatopa | Glatiramer Acetate | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Lamictal | Lamotrigine | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,076.87 · 184 records | PFIZER INC. | AMYVID, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CREXONT, DAYBUE, EPIDIOLEX, Enspryng, FYCOMPA, GOMEKLI, HYQVIA, KESIMPTA, KEVEYIS, KISUNLA, LEQEMBI, NUPLAZID, NURTEC ODT, Nayzilam, OZOBAX, Ocrevus Zunovo, PONVORY, QULIPTA, QUTENZA, REXULTI, Rystiggo, TRUDHESA, TYSABRI, UBRELVY, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error